Traduction de «driven by phasing of clinical trial activities » (Néerlandais → Français) :

R&D improved 0.3 percentage points, mainly driven by phasing of clinical trial activities.
La R&D s’est améliorée de 0,3 point, essentiellement à la suite d’un étalement dans le temps des essais cliniques.

R&D increased 0.3 percentage points, mainly driven by phasing of clinical trial activities.
Recherche et développement s’est amélioré de 0,3 point, essentiellement à la suite d’un étalement des essais cliniques dans le temps.

R&D improved 0.7 percentage points, mainly driven by phasing of clinical trial activities.
La R&D s’est améliorée de 0,7 point de pourcentage, essentiellement à la suite d’un étalement dans le temps des essais cliniques.

However, the figures do clearly show that there is a considerable number of early phase trials. There are 7 units in Belgium actively undertaking phase I clinical trials and a number of early phase trials are being conducted in centres where there is expertise in specific clinical areas.
However, the figures do clearly show that there is a considerable number of early phase trials. There are 7 units in Belgium actively undertaking phase I clinical trials and a number of early phase trials are being conducted in centres where there is expertise in specific clinical areas.

QAB149 (indacaterol), a bronchodilator in development for Chronic Obstructive Pulmonary Disease (COPD), has been shown in Phase III clinical trials to significantly improve lung function over the currently available treatments formoterol and tiotropium at three months of therapy.
QAB149 (indacatérol), un bronchodilatateur en développement pour traiter la bronchopneumopathie chronique obstructive (BPCO), a montré, dans des essais cliniques de phase III que, au bout de trois mois, il améliorait notablement la fonction pulmonaire par rapport aux traitements à base de formotérol et tiotropium disponibles actuellement.

In 2008, there was a significant increase observed in the number of applications for clinical trials and amendments (changes to an existing file) and of the percentage of phase I trials. The absolute number of non-commercial (“academic”) trials remained stable.
In 2008, there was a significant increase observed in the number of applications for clinical trials and amendments (changes to an existing file) and of the percentage of phase I trials. The absolute number of non-commercial (“academic”) trials remained stable.

The number of early phase trials is per capita one of the highest in Europe. Since the publication of the guideline trials for conducting explorative studies in Belgium, in mid June 2007, 25 applications for conducting these clinical trials have been submitted to the FAMHP.
The number of early phase trials is per capita one of the highest in Europe. Since the publication of the guideline trials for conducting explorative studies in Belgium, in mid June 2007, 25 applications for conducting these clinical trials have been submitted to the FAMHP.

One striking point is the clear trend towards an increasing number of phase I trials, from 17% in 2004 to 24% in 2007, as well as the increase in the number of submitted academic clinical trials: from 3% in 2004 to 7% in 2007.
One striking point is the clear trend towards an increasing number of phase I trials, from 17% in 2004 to 24% in 2007, as well as the increase in the number of submitted academic clinical trials: from 3% in 2004 to 7% in 2007.

The FAMHP intends to significantly increase its involvement in the lifecycle of immunological medicines for veterinary use by providing scientific advice, evaluating applications for clinical trials in Belgium, adopting (co-)rapporteurships for CP, MRP and DCP for MA of vaccines for veterinary use and developing pharmacovigilance and inspection activities.
The FAMHP intends to significantly increase its involvement in the lifecycle of immunological medicines for veterinary use by providing scientific advice, evaluating applications for clinical trials in Belgium, adopting (co-)rapporteurships for CP, MRP and DCP for MA of vaccines for veterinary use and developing pharmacovigilance and inspection activities.

Data from a one-year Phase III trial published in “The New England Journal of Medicine” in June confirmed that Ilaris offered rapid and long-term clinical remission in CAPS patients.
Des données d’un essai de phase III sur un an publiées en juin dans «The New England Journal of Medicine» ont confirmé qu’Ilaris offrait une rémission clinique rapide et de longue durée des CAPS.